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Objective
　Various markers of bone metabolism are used to help develop treatment plans for osteo-
porosis or for assessing therapeutic effects of osteoporosis medications.  Many investigations 
have examined the effects of various bone metabolism markers 1-3）, but few have examined 
correlations across multiple types of bone metabolism markers.  We investigated correlations 
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Abstract : Various markers of bone metabolism are used in the treatment of 
osteoporosis as they can help assess the condition of bony tissue/bone metabo-
lism and can help predict the likelihood of fractures and bone loss in the near 
future.  We investigated correlations between various bone metabolism markers 
to ascertain which could be used as a universal marker of bone metabolism 
and its associated care.  Subjects comprised 144 female patients treated for 
osteoporosis at this facility between January and December 2009, in whom the 
following bone metabolism markers were measured on the same day : BAP, 
urine NTX, OC, ucOC, and TRACP-5b.  The mean age of the subjects was 
71.2 years.  All subjects were analyzed as an entire group （total group）, and 
subjects were also divided into 2 groups and analyzed based on whether they 
were using an osteoporosis drug or not.  Subjects currently being treated were 
included in the treated group （n=113 ; mean age : 71.9 years）.  Subjects with 
no treatment experience were included in the untreated group （n=31 ; mean 
age : 68.6 years）.  In the total group and treated group, signicant correlations 
were revealed between BAP, urine NTX, OC, ucOC, and TRACP-5b.  In 
the untreated group, no correlation was observed between BAP and ucOC, 
but correlations between BAP, urine NTX, OC, ucOC, and TRACP-5b were 
observed.  ucOC is a marker of bone metabolism, and is also an indicator 
of the state of vitamin K intake.  Based on the correlations with both bone 
resorption markers and osteoplastic markers found in this study, ucOC was 
found to be the best universal marker to use in the clinical setting.
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between various bone metabolism markers to determine which could be used as a universal 
marker of bone metabolism and its associated care.
Subjects and Methods
　Subjects comprised female patients treated for osteoporosis at this facility between January 
and December 2009 in whom the following bone metabolism markers were measured on 
the same day : bone alkaline phosphatase （BAP）; cross-linked N-telopeptide of type I col-
lagen （urine NTX）; osteocalcin （OC）; undercarboxylated osteocalcin （ucOC）; and tartrate-
resistant acid phosphatase （TRACP-5b）.  There were 144 subjects, with a mean age of 71.2 
years （range : 34-92 years）.  The pathology underlying the need for treatment was primary 
osteoporosis in 141 subjects, and secondary osteoporosis in 3 subjects （steroid induced in 2 
subjects ; ovarian failure in 1 subject）.
　BAP, urine NTX, OC, ucOC, and TRACP-5b levels were measured at the initial visit or 
during a periodic checkup.  In addition, samples were taken for hematology.  Blood and 
urine biochemistry, and urine Ca/Cr levels were also investigated.  Urine NTX and urine 
Ca/Cr were measured from the second morning urine.
　All 144 subjects were analyzed as a total group.  The subjects were also divided into 2 
groups and analyzed based on whether they were using an osteoporosis drug or not.  Sub-
jects currently using osteoporosis medications were included in the treated group （n=113 ; 
mean age : 71.9 years）, and subjects with no treatment experience were included in the 
untreated group （n=31 ; mean age : 68.6 years）.  Drugs used by subjects in the treated 
group were as follows : 14 patients took etidronate （drug alone : n=8 ; concomitant vitamin 
D : n=3 ; concomitant calcium : n=3）; 34 patients took alendronate （drug alone : n=20 ; con-
comitant vitamin D : n=12 ; concomitant calcium : n=2）; 27 patients took risedronate （drug 
alone : n=17 ; concomitant vitamin D : n=5 ; concomitant calcium : n=2 ; concomitant vitamin 
K : n=1 ; concomitant vitamin D and calcium : n=1 ; concomitant vitamin D and vitamin K : 
n=1）; 10 patients took raloxifene （drug alone : n=8 ; concomitant vitamin D : n=1 ; concomi-
tant calcium : n=1）; 3 patients took vitamin K ; 16 patients took vitamin D ; 6 patients took 
vitamin D and calcium ; 1 patient took calcium ; 1 patient took vitamin K and calcium ; and 
one patient took conjugated estrogens.  2 subjects were taking warfarin in the present study.
　Data were statistically analyzed using Pearson’s correlation coefcient with a two-tailed 
signicance level of P＜ 0.05.  Statistical analysis was performed using Stat Mate III version 
3.14 （ATMS, Tokyo, Japan）.
　The study protocol was reviewed and approved by the Medical Ethics Review Board of 
Showa University School of Medicine （approval number : 1053）.
Results
　In the total group, significant differences between parameters were observed for BAP, 
urine NTX, OC, ucOC, and TRACP-5b （P＜ 0.05 to P＜ 0.001 ; Fig. 1a-c）.  No correlations 
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with urine Ca/Cr were observed （Table 1）.  In the treated group, signicant correlations 
between BAP, urine NTX, OC, ucOC, and TRACP-5b were observed （Table 2）.  No cor-
relations with urine Ca/Cr were apparent.  In the untreated group, no signicant correlation 
was observed between BAP and ucOC, but correlations between BAP, urine NTX, OC, 
ucOC, and TRACP-5b were observed （Table 3）.  No correlation was seen between urine 
Ca/Cr and any other parameter.
Discussion
　Clinical measurement of bone metabolism markers enables the condition of bony tissue/
bone metabolism to be assessed 1）, allows prediction of fracture risk 4, 5） and risk of bone loss 
in the near future 2）, and enables drug therapies for osteoporosis to be practically assessed. 
In addition, conveying these results to patients can help increase patient compliance in 
taking osteoporosis medications.  Results can also be used to screen for bone metastases 
from tumorous lesions 6）.  Changes in bone metabolism markers can occur due to age, sex, 
a
b c
Fig. 1.   Correlation between bone metabolism markers in the total group. Significant correlations were 
observed between BAP, urine NTX, TRACP-5b, OC, and ucOC.
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Table 1.  Correlations between parameters in the total group.
N=144
BAP U-NTX OC ucOC TRAPC-5b U-Ca/Cr
BAP P＜ 0.001 P＜ 0.001 P＜ 0.001 P＜ 0.001 NS
U-NTX P＜ 0.001 P＜ 0.001 P＜ 0.001 P＜ 0.001 NS
OC P＜ 0.001 P＜ 0.001 P＜ 0.001 P＜ 0.001 NS
ucOC P＜ 0.001 P＜ 0.001 P＜ 0.001 P＜ 0.001 NS
TRAPC-5b P＜ 0.001 P＜ 0.001 P＜ 0.001 P＜ 0.001 NS
U-Ca/Cr NS NS NS NS NS
Significant correlations were observed between urine NTX, BAP, TRACP-5b, OC, and ucOC. 
Urine Ca/Cr levels did not correlate with any parameter.
Table 2.  Correlations between parameters in the treated group.
N=113
BAP U-NTX OC ucOC TRAPC-5b U-Ca/Cr
BAP P＜ 0.001 P＜ 0.001 P＜ 0.001 P＜ 0.001 NS
U-NTX P＜ 0.001 P＜ 0.001 P＜ 0.001 P＜ 0.001 NS
OC P＜ 0.001 P＜ 0.001 P＜ 0.001 P＜ 0.001 NS
ucOC P＜ 0.001 P＜ 0.001 P＜ 0.001 P＜ 0.001 NS
TRAPC-5b P＜ 0.001 P＜ 0.001 P＜ 0.001 P＜ 0.001 NS
U-Ca/Cr NS NS NS NS NS
Significant correlations were observed between urine NTX, BAP, TRACP-5b, OC, and ucOC.
Table 3.  Correlations between parameters in the untreated group.
N=31
BAP U-NTX OC ucOC TRAPC-5b U-Ca/Cr
BAP P＜ 0.01 P＜ 0.05 NS P＜ 0.05 NS
U-NTX P＜ 0.01 P＜ 0.001 P＜ 0.001 P＜ 0.001 NS
OC P＜ 0.05 P＜ 0.001 P＜ 0.001 P＜ 0.001 NS
ucOC NS P＜ 0.001 P＜ 0.001 P＜ 0.01 NS
TRAPC-5b P＜ 0.05 P＜ 0.001 P＜ 0.001 P＜ 0.01 NS
U-Ca/Cr NS NS NS NS NS
Although no correlation was observed between BAP and ucOC, correlations were observed 
between urine NTX, BAP, TRACP-5b, OC, and ucOC.
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menopause, drugs, fracture 3）, diabetes mellitus, and thyroid dysfunction 7, 8）.  In general, bone 
metabolism becomes more active at night than during the day, and after decreasing in the 
afternoon, almost all markers of bone metabolism are present at high levels at night then 
decrease in the morning 9, 10）.  As a result, samples must be taken within the same time 
frame.  In the present study, most of the patients had primary osteoporosis, and their results 
could not be compared to the results from the 3 patients with secondary osteoporosis 
because of the small number.  By increasing the number of subjects, we hope to conduct 
further analyses on correlations between bone metabolism markers and the causes of osteo-
porosis, such as in patients with steroid-induced secondary osteoporosis.
　Various types of bone metabolism markers are known, but the present study only 
measured BAP, urine NTX, OC, ucOC, and TRACP-5b.  The results revealed correlations 
between the various markers.  Hosoi11） reported that TRACP-5b and NTX were signicantly 
correlated （P＜ 0.0001）.  Both are regarded as effective markers for ascertaining the condi-
tion of bone metabolism in osteoporosis.  However, each of these markers has a very wide 
range of normal values, ranging from 1 to 3 decimal places.  This wide range of normal 
values can be advantageous in conducting drug therapy.  If markers of bone metabolism 
show a large improvement, patient compliance in the clinical setting can increase, as larger 
variations in values appear to reect drug efcacy more acutely than small variations.  We 
believe that U-NTX is a more useful marker for the evaluation of bone resorption ; on 
the other hand, BAP is more useful as an osteoplastic marker.  In addition, although two 
types of bone metabolism markers are available （bone resorption markers and osteoplastic 
markers）, the therapeutic effect of osteoporosis drugs is better assessed in clinical practice 
when the same type of bone metabolism marker is tested, rather than changing the type of 
marker with each test.  In the present study, urine Ca/Cr levels showed no correlation with 
any other marker of bone metabolism in either the total group, untreated group, or treated 
group.  However, we reported previously that signicant differences in urine Ca/Cr levels are 
effective for assessing therapeutic effects 12）.  In view of the results from the present study, 
although problems remain with the use of urine Ca/Cr levels as a single indicator of bone 
metabolism, it is still a necessary parameter for the early detection of hypercalciuria.
　In the total group and the treated group, ucOC correlated with urine NTX, BAP, OC, 
and TRACP-5b.  However, there was no correlation between ucOC and BAP in the 
untreated group.  Although ucOC is a marker of bone metabolism, it is also useful as an 
indicator of the state of vitamin K intake 13）.  Vitamin K has an effect on the blood coagu-
lation system, but an antagonistic action occurs when vitamin K is administered to patients 
taking the anticoagulant warfarin.  As a result, caution is necessary when administering 
vitamin K to patients on warfarin.  Vitamin K also functions as a coenzyme of γ-glutamyl 
carboxylase.  Gamma-glutamyl carboxylase catalyzes the carboxylation of glutamate （Glu） 
residues in vitamin-K-dependent proteins to produce γ-carboxyglutamate （Gla） residues.  A 
negative correlation exists between the formation of Gla and osteoporotic fractures 14, 15）. 
Takashi NAGAI, et al170
Low Gla-osteocalcin blood levels were reportedly more common in a group of patients 
with fractures than in a control group, and the incidence of new femoral neck fracture was 
higher in the group with a higher incidence of low Gla-osteocalcin blood levels 14）.  Only 
2 subjects were taking warfarin in the present study.  The ucOC level was slightly higher 
in case 1 and remarkably higher in case 2 than the average level （Table 4）.  We think 
ucOC level was higher in the warfarin treated group because the intake of vitamin K was 
restricted in that group.
　The ultimate objective of osteoporosis treatment is fracture prevention.  Although mark-
ers of bone metabolism are useful for their evaluative and predictive properties, conducting 
simultaneous tests with many markers is not economical.  ucOC is a marker of bone 
metabolism, and also indicates the state of vitamin K intake.  Based on the results from 
this study, the correlations between both bone resorption markers and osteoplastic markers 
identied ucOC as the best universal bone metabolism marker to use in the clinical setting.
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